A targeted transport of 125I-labeled monoclonal antibodies to target proteins in experimental glioma focus.

The targeted transport of radioactive preparations to glioblastoma focus with the help of antibodies recognizing the target antigen selectively expressed in the tumor underlies the state-of-the-art methods of radioimmune diagnostics and therapy [10]. The existing methods of radioimmune localization using the antibodies to fibronectin [6], tenascin [2], growth factor receptors [9], and endothelial antigens [3, 5] are accompanied by an essential “background” irradiation of intact organs and tissues due to an insufficient specificity of the listed antigens for the tumor. Consequently, the search for new target proteins specific of glioblastoma is most topical for a targeted transport of diagnostic and therapeutic preparations. We have earlier demonstrated an increased expression of the glial fibrillary acid protein (GFAP) at the periphery of C6 glioma (in the region of astroglial border) as well as of the endotheliocyte abluminal membrane antigen (AMVB1), which we described earlier, in the tumor microvessels [1]. The goal of this work was to assess the capture selectivity of tumor tissue towards the monoclonal antibodies to GFAP and AMVB1 injected intravenously to the rats with experimentally induced C6 glioma, which is most close to the human glioblastoma multiforme [4, 7].